...Herpes zoster vaccine) Swedish Orphan Biovitrum AB Stemline Therapeutics Inc. GlaxoSmithKline plc AstraZeneca plc Adheron Therapeutics Inc. Gilead Sciences Inc. Blueprint Medicines Corp. Insmed...

...company has raised more than $1.9 billion in four venture rounds. Insmed, Kura price follow-ons Insmed...
...Schlaepfer Family Foundation. Targets AXL (UFO) - AXL receptor tyrosine kinase BioCentury Staff Kineta Inc. BerGenBio A/S Limbix Kura Oncology Inc. Insmed Pharmaceuticals Inc....

...and a miss for the high dose on a secondary endpoint, raise questions about how Insmed’s...
...from baseline of activated ELANE, another secondary endpoint (p=0.034 and p=0.021, respectively). A spokesperson for Insmed...
...stopped selling the IGF-1 receptor agonist to new patients (see “Insmed combines with Transave” ). Insmed...

...who will become CMO of Bavarian Nordic A/S (CSE:BAVA; Pink:BVNRY) in April, rare disease company Insmed...
...and Elizabeth S. Eaton, Staff Writers Cell and Gene Therapy Catapult Los Angeles Biomedical Research Institute SutroVax Inc. NeoImmuneTech Inc. Insmed...

...president, CSO and board member at immuno-oncology company Tollnine, which he co-founded. Rare diseases company Insmed...
...Affimed N.V. (NASDAQ:AFMD). Jonathan Block, Associate Editor Jonathan Block, Associate Editor, and Hongjiang Li, Staff Writer Lonza Group Ltd. Insmed...

...Inc . (NASDAQ:EPZM) hired Paolo Tombesi as CFO, effective next month. He was CFO at Insmed...

...5/23/19 $319.5 $6,504.5 $7,908.9 22% OncoSec Medical Inc. (NASDAQ:ONCS) (A) 5/22/19 $11.0 NA $26.9 NA Insmed...

...VP and CFO, succeeding Ivor MacLeod. Coyle was VP of financial planning and analysis at Insmed...

...Insmed raises $250M follow-on Insmed Inc. (NASDAQ:INSM) raised $250 million in a follow-on through the sale...
...discount to Insmed's Monday close of $28.07, when it proposed the offering after market close. Insmed...
...BIO101), a MAS receptor agonist in Phase IIb testing to treat sarcopenia. Chris Lieu, Staff Writer Biophytis S.A. Insmed Pharmaceuticals Inc. Inhibrx...

...Pulmonary disease company Insmed said Paolo Tombesi will step down as CFO and remain a consultant...
...said Paolo Tombesi will step down as CFO and remain a consultant, effective June 2. Insmed...
...Kola, who was CSO at UCB S.A. (Euronext:UCB), will lead Forepont's Incubation Fund. BioCentury Staff AACR BlueRock Therapeutics Celyad S.A. Insmed...